Alpha-tocopherol |
Preclinical |
Reduced oxidative stress, behavioral abnormalities, learning deficits in FXS mice |
de Diego-Otero et al., 2009
|
Vitamin B6+ magnesium (Mg) |
Clinical |
Improved core symptoms of ASD |
Nye and Brice, 2005
|
Vitamin B12 |
Clinical |
Reduced ASD related metabolic dysfunctions, irritability, aggression in children with ASD |
Malhotra et al., 2013
|
Vitamin D and Omega-3 fatty acids |
Clinical |
Reduced hyperactivity and irritability among autistic children |
Mazahery et al., 2019
|
Folinic acid |
Clinical |
Improved social behavior and cognition deficits in children with ASD |
Frye et al., 2013
|
Lithium |
Preclinical |
Mood stabilizers in ASD; reduced hyperactivity, anti-social behaviors, cognition deficits in FXS mice |
Liu et al., 2011; Mintz and Hollenberg, 2019
|
Omega-3 fatty acids |
Preclinical |
Improved ultrasonic vocalizations and social discriminations in rat models with ASD and FXS; improved emotion, non-spatial memory, social interactions and neuroinflammation in FXS mice |
Pietropaolo et al., 2014; Schiavi et al., 2022
|
Breast milk |
Retrospective clinical |
Reduced incidence of autism in FXS |
Westmark, 2021b
|
Specific carbohydrate diet |
Clinical |
Improved GI symptoms, behavioral abnormalities, and nutritional status in a child with both FXS and ASD |
Barnhill et al., 2020
|
Ketogenic diet |
Preclinical |
Improved epilepsy, repetitive behavior, social skills, impaired learning skill in mice with ASD; Improved social exploration and interactions in rodents; reduced hyperactivity and seizures in mouse model of FXS |
Ruskin et al., 2013; Castro et al., 2017; Westmark et al., 2020b
|
Soy vs. casein-based rodent diet |
Preclinical |
Increased seizures and weight gain with soy |
Westmark et al., 2013, Westmark et al., 2022
|
Soy vs. casein-based infant formulas |
Retrospective clinical |
Increased seizures, autism, GI problems and allergies in ASD and FXS populations with soy |
Westmark, 2013, 2014a, 2017, 2021a; Westmark et al., 2020a
|